抗体
试剂盒
多肽
探针
蛋白
组织芯片
产品中心
Product Center
Research Grade Lirilumab
All
TD-HW759016_1.jpg
TD-HW759016_2.jpg
TD-HW759016_3.jpg
- Catalog： TD-HW759016
- Clonality： mAb
- Application： Research Grade Biosimilar
- Synonyms： BMS-986015,IPH2102,CAS:1000676-41-4
-
规格：
1mg
-
价格：
¥询价
定制服务咨询
Research Grade Lirilumab
| Catalog No. | TD-HW759016 |
|---|---|
| Species reactivity | Human |
| Applications | Research Grade Biosimilar |
| Host species | Human |
| Isotype | IgG4-kappa |
| Expression system | XtenCHO |
| Clonality | Monoclonal |
| Target | CD158 antigen-like family member A, KIR2DL1, Killer cell immunoglobulin-like receptor 2DL1, Natural killer-associated transcript 1, NKAT-1, MHC class I NK cell receptor, CD158A, p58 natural killer cell receptor clones CL-42/47.11, CD158a, p58.1 MHC class-I-specific NK receptor, NKAT1, p58 NK receptor CL-42/47.11, p58 NK receptor CL-43, NKAT-6, NKAT6, MHC class I NK cell receptor, CD158 antigen-like family member B1, CD158b1, p58 natural killer cell receptor clone CL-43, Natural killer-associated transcript 6, CD158B1, KIR2DL2, Killer cell immunoglobulin-like receptor 2DL2, NKAT2b, KIR2DL3, p58 natural killer cell receptor clone CL-6, p58.2 MHC class-I-specific NK receptor, CD158 antigen-like family member B2, MHC class I NK cell receptor, KIR-023GB, Killer inhibitory receptor cl 2-3, p58 NK receptor CL-6, CD158b2, Killer cell immunoglobulin-like receptor 2DL3, Natural killer-associated transcript 2, CD158B2, KIRCL23, NKAT-2, NKAT2a, NKAT2 |
| Endotoxin level | Please contact the lab for this information. |
| Purity | >95% purity by SDS-PAGE. |
| Purification | Protein A/G, purified from cell culture supernatant. |
| Accession | P43626 & P43627 & P43628 |
| Form | Liquid |
| Storage buffer | 0.01M PBS,pH7.4. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | BMS-986015,IPH2102,CAS:1000676-41-4 |
| Background | Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research. |
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|
|
SEC-HPLC detection for Research Grade Lirilumab. |
|
|
Detects Human CD158b1/KIR2DL2 in indirect ELISAs. |
|
|
SDS-PAGE for Research Grade Lirilumab. |